Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 0904-6478

15 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 0904-6478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Bc153659 2091 4682 A63b 8735e1146bac 14)

Structural Formula (Bc153659 2091 4682 A63b 8735e1146bac 14)
Chemical structure of Donepezil Hydrochloride, showing molecular components and arrangement including aromatic rings, methoxy groups, a piperidine ring, and hydrochloride as depicted in the image.*
FDA Label Image

Figure 1 (Bc153659 2091 4682 A63b 8735e1146bac 13)

Figure 1 (Bc153659 2091 4682 A63b 8735e1146bac 13)
A line graph showing the mean change in ADAS-cog scores from baseline over weeks of drug treatment for Donepezil Hydrochloride tablets at 10 mg/day and 5 mg/day doses, compared to placebo. The vertical axis represents ADAS-cog change, with clinical improvement above baseline and clinical decline below. The horizontal axis shows weeks of treatment up to 30 weeks, including a placebo period. Error bars indicate standard error.*
FDA Label Image

Figure 2 (Bc153659 2091 4682 A63b 8735e1146bac 12)

Figure 2 (Bc153659 2091 4682 A63b 8735e1146bac 12)
A cumulative percentage plot showing patients' change from baseline in ADAS-cog scores for Donepezil Hydrochloride Tablets 5 mg/day, 10 mg/day, and placebo groups. The graph includes specific change points at -7, -4, and 0 and a table summarizing percentage changes in the treatment groups at these points.*
FDA Label Image

Figure 3 (Bc153659 2091 4682 A63b 8735e1146bac 11)

Figure 3 (Bc153659 2091 4682 A63b 8735e1146bac 11)
Bar chart comparing the percentage of patients by CIBIC-plus rating categories among three groups: Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo. The x-axis shows clinical improvement/worsening ratings from 'Markedly Improved' to 'Markedly Worse,' and the y-axis shows percentage of patients up to 50%. The chart displays the distribution of patients across these categories for each treatment group.*
FDA Label Image

Figure 4 (Bc153659 2091 4682 A63b 8735e1146bac 10)

Figure 4 (Bc153659 2091 4682 A63b 8735e1146bac 10)
A line graph depicting the mean change from baseline in ADAS-cog scores over weeks of drug treatment for Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses compared to placebo. The x-axis shows weeks of treatment up to 12 with an additional placebo period, while the y-axis shows ADAS-cog change from baseline, indicating clinical improvement above baseline and clinical decline below baseline. Data points demonstrate greater clinical improvement for both Donepezil doses compared to placebo over time, with 10 mg/day showing the most pronounced effect.*
FDA Label Image

Figure 5 (Bc153659 2091 4682 A63b 8735e1146bac 09)

Figure 5 (Bc153659 2091 4682 A63b 8735e1146bac 09)
A cumulative percentage of patients graph showing change from baseline on the x-axis and cumulative percentage on the y-axis. It compares Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses versus placebo. The chart includes markers for 7 points, 4 points, and no change, with a table showing percentage changes in ADAS-cog scores for placebo, 5 mg/day, and 10 mg/day treatment groups at different change levels (-7, -4, 0).*
FDA Label Image

Figure 6 (Bc153659 2091 4682 A63b 8735e1146bac 08)

Figure 6 (Bc153659 2091 4682 A63b 8735e1146bac 08)
A bar chart comparing the distribution of CIBIC-plus Ratings among patients treated with Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo. The chart shows the percentage of patients rated from Markedly Improved to Markedly Worse, illustrating relative patient outcomes across these three groups.*
FDA Label Image

Figure 7 (Bc153659 2091 4682 A63b 8735e1146bac 07)

Figure 7 (Bc153659 2091 4682 A63b 8735e1146bac 07)
A line graph depicting SIB (Severe Impairment Battery) change from baseline over 6 months of treatment. The graph compares Donepezil Hydrochloride Tablets 10 mg/day and placebo, showing clinical improvement and decline on the y-axis and months of drug treatment on the x-axis. Donepezil shows an increase in SIB score, indicating improvement, while placebo shows a decline.*
FDA Label Image

Figure 8 (Bc153659 2091 4682 A63b 8735e1146bac 06)

Figure 8 (Bc153659 2091 4682 A63b 8735e1146bac 06)
A cumulative percentage of patients chart comparing Donepezil Hydrochloride Tablets 10 mg/day (solid circles) and placebo (open squares) against SIB (Severe Impairment Battery) change from baseline. The x-axis shows SIB change from baseline values, and the y-axis indicates the cumulative percentage of patients, illustrating a distribution shift favoring the Donepezil treatment over placebo.*
FDA Label Image

Figure 9 (Bc153659 2091 4682 A63b 8735e1146bac 05)

Figure 9 (Bc153659 2091 4682 A63b 8735e1146bac 05)
A line graph showing the time course of the change from baseline in ADCS-ADL-Severe Score for patients completing 6 months of treatment. The x-axis represents months of drug treatment (0, 3, 6), and the y-axis shows mean change from baseline score with standard error bars. Two lines compare Donepezil Hydrochloride Tablets 10 mg/day and placebo, illustrating a decline in scores over 6 months with a smaller decline for donepezil, indicating clinical improvement versus clinical decline.*
FDA Label Image

Figure 10 (Bc153659 2091 4682 A63b 8735e1146bac 04)

Figure 10 (Bc153659 2091 4682 A63b 8735e1146bac 04)
A cumulative percentage curve chart comparing Donepezil Hydrochloride Tablets 10 mg/day with placebo. The x-axis represents ADCS-ADL change from baseline, ranging from -20 to 20, while the y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves plot patient response distributions for each treatment group.*
FDA Label Image

Logo (Bc153659 2091 4682 A63b 8735e1146bac 03)

FDA Label Image

Logo 1 (Bc153659 2091 4682 A63b 8735e1146bac 02)

FDA Label Image

5mg Carton Label (Bc153659 2091 4682 A63b 8735e1146bac 01)

5mg Carton Label (Bc153659 2091 4682 A63b 8735e1146bac 01)
Donepezil Hydrochloride 5 mg film-coated tablets unit dose packaging label by Major Pharmaceuticals. The label includes the NDC 0904-6477-61, directions for pharmacist to dispense with patient information sheet, total of 100 tablets (10 x 10), and states Rx only. Additional labeling provides storage instructions, dosing notes, and safety warnings, indicating the packaging is intended for institutional use and is not child resistant.*
FDA Label Image

10mg Carton Label (Bc153659 2091 4682 A63b 8735e1146bac 00)

10mg Carton Label (Bc153659 2091 4682 A63b 8735e1146bac 00)
Packaging label for Donepezil Hydrochloride tablets, USP, 10 mg film-coated oral tablets by Major Pharmaceuticals. The label shows NDC 0904-6478-61 and indicates unit dose packaging with 100 tablets (10 x 10 count). It includes dispensing instructions and storage conditions, noting this unit dose package is not child resistant and is for institutional use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.